ISTANBUL (Reuters): BioNTech SE said on Thursday (May 20) the Covid-19 vaccine it developed with Pfizer should be roughly as effective against the new coronavirus variant first detected in India as it has been shown to be against the South African variant.
The company said in a statement Chief Executive Ugur Sahin felt encouraged by recent findings in a scientific paper https://www.biorxiv.org/content/10.1101/2021.05.09.443299v1 based on blood analysis of vaccinated individuals, which showed that the antibodies elicited by the vaccine were able to neutralise the Indian variant.
Already a subscriber? Log in.
Win a prize this Mother's Day by subscribing to our annual plan now! T&C applies.
Cancel anytime. No ads. Auto-renewal. Unlimited access to the web and app. Personalised features. Members rewards.
Follow us on our official WhatsApp channel for breaking news alerts and key updates!
